Production Capability and Outsourcing Trends of Japanese Pharmaceutical Companies 2010 (Japanese version)
Outline of the report
With the revision of the Pharmaceutical Affairs Law in April 2005, Japanese pharmaceutical companies revised their production capabilities and have pushed on corporate restructuring and split-ups. Companies such as Astellas and Daiichi-Sankyo have split-up all their production facilities and are actively restructuring affiliated companies. Global movements are also visible as Eisai has constructed new production and research centers for API and formulations in India and Takeda is consolidating the management of its API production facilities in Ireland.
In addition to the integration and closing of production facilities, companies are now outsourcing their production capacity aiming to reduce costs and to improve productivity. Also quality assurance and quality control (QA/QC) systems are being strengthened.
This report is the revised edition of the 2008 report, which covers the changes in production capabilities and outsourcing status of Japanese companies of the three years. This report will aid in connecting pharmaceutical companies with contract manufacturing organizations (CMOs).
| Title of the report | Production Capability and Outsourcing Trends of Japanese Pharmaceutical Companies 2010 (Japanese version) |
| Date of issue | 07/07/10 |
| Volume | A4 / 236 pages |
| Price | 120,000JPY |
| Produced by | Seed Planning, Inc. |
| Note | This report is written in Japanese. An english summary is available with additional fee for translation. For customers who need the english summary please contact us. Report code: J123816 |
| Category | Pharmaceutical products / compaines / Pharmaceutical materials / vendors / Pharmaceutical industry |
Details of the report
Target Companies
- 50 Major Companies
- Asahi Kasei Pharma, ASKA Pharmaceuticals, Astellas Pharma, AstraZeneca, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Kyorin Pharmaceutical, GlaxoSmithKline, Kowa, Kobayashi Kako, Zydus Pharma, Sanofi-Aventis, Sawai Pharmaceutical, Santen Pharmaceutical, Shionogi, ZERIA Pharmaceutical, Daiichi Sankyo, Taisho Pharmaceutical, Dainippon Sumitomo Pharma, Taiho Pharmaceutical, Taiyo Yakuhin, Takeda Pharmaceutical, Tatsumi Kagaku, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Choseido Pharmaceutical, Tsumura, Terumo, Oriental Pharmaceutical and Synthetic Chemical, Towa Pharmaceutical, Toyama Chemical, Nichi-iko Pharmaceutical, Eli Lilly Japan, Nippon Kayaku, Nissin Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, Bayer HealthCare, Banyu Pharmaceutical, Hisamitsu Pharmaceutical, Pfizer Japan, Fuso Pharmaceutical, Mylan, Meiji Seika, Mochida Pharmaceutical
Table of Contents
- 1. Company Profile
- 2. Production Capability Outline
- Production-related Organization Chart (Supply chain, Process Chart, Production Facilities)
- 3. Breakdown of Production Facilities
- Company name, Facility name, Location, Size (Site area, Production workforce), Production process, Product portfolio
- 4. Recent Trends in Production Equipment to 2010
- 5. CMOs used
- 6. Production Capability
- Background of Split-outs and Integrations, Locations of Production Facilities, Directions toward Enhancing Production Capability
- 7. Production Outsourcing
- Outsourcing Contacts, Outsourcing Status
- 鐚Research Questionnaire鐚
-
鐚Available only for companies which responded to the questionnaire
(1)Current status on outsourcing of pharmaceutical production (by process, category and product, and percentage)
(2)Increases/decreases of outsourcing in the past 3 years
(3)Breakdown of increasingly outsourced production technologies (by process, category and product)
(4)Availability of outsourcing contracts and trading methods
(5)Section responsible for outsourcing contracts and its role (contact/orders, gathering information, considerations, decision making)
(6)Structural changes related to production outsourcing in the past 3 years
(7)Future policies toward outsourcing
(8)Challenges and opinions toward production/outsourcing (Open-ended)
(9)QA/QV personnel (number of employees, increase/decrease in numbers)
